F10 and Stroke: Direct oral anticoagulants (DOACs), direct oral thrombin inhibitor dabigatran, and direct oral factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have emerged as a preferred choice for long-term prevention of stroke in AF patients [5] offering potent and predictable anticoagulation and a favorable pharmacology with low risk of interactions.